Physician profile
Wei Wei Li
NPI 1720246465
$1,557.30
in general payments reported to CMS, 2019-2025
13 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.70 · 2020: $37.03 · 2021: $464 · 2022: $170 · 2023: $269 · 2024: $414 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $506.08 | 2019-2025 | |
| Genentech USA, INC. | $290.72 | 2019-2024 | Xolair |
| Glaxosmithkline, LLC. | $203.00 | 2021-2022 | |
| Pharming Healthcare, INC. | $137.36 | 2023 | Ruconest |
| Dermavant Sciences, INC. | $117.93 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $81.93 | 2024-2025 | |
| Alk-Abello, INC | $51.14 | 2021 | |
| Saranas, INC. | $49.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $47.41 | 2022-2025 | Tezspire |
| Abbvie INC. | $25.69 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.12 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $16.45 | 2022 | |
| Phadia US INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wei Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.